Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine in healthy Chinese females aged 15 to 45 years: a phase I trial.
- Author:
Feng-Cai ZHU
1
;
Chang-Gui LI
;
Hong-Xing PAN
;
Yi-Ju ZHANG
;
Dan BI
;
Hai-Wen TANG
;
Sanjoy DATTA
Author Information
- Publication Type:Journal Article
- MeSH: Adjuvants, Immunologic; Adolescent; Adult; Antibodies, Viral; blood; Asian Continental Ancestry Group; China; Female; Human papillomavirus 16; immunology; Human papillomavirus 18; immunology; Humans; Middle Aged; Papillomavirus Infections; immunology; prevention & control; virology; Papillomavirus Vaccines; administration & dosage; adverse effects; therapeutic use; Uterine Cervical Neoplasms; immunology; prevention & control; virology; Young Adult
- From:Chinese Journal of Cancer 2011;30(8):559-564
- CountryChina
- Language:English
- Abstract: Globally, about 70% of cervical cancers are associated with human papillomavirus (HPV)-16 or HPV-18 infection. A meta-analysis of epidemiologic studies in China showed that HPV was present in 98% of cervical cancer samples. The HPV-16/18 AS04-adjuvanted vaccine Cervarix has shown a high level of protection against HPV-16/18 infections and associated cervical lesions. This phase I trial (NCT00549900) assessed the safety, tolerability, and immunogenicity of the vaccine in Chinese. Thirty healthy Chinese females, aged 15 to 45 years with a median age of 29.5 years, received three doses of Cervarix in Months 0, 1, and 6. Safety was assessed via recording solicited local and systemic symptoms within 7 days and unsolicited symptoms within 30 days after each vaccination. Serious adverse events, new onset of chronic diseases, and other medically significant conditions were recorded throughout this trial. As an exploratory objective, HPV-16/18 antibody titers were determined by enzyme-linked immunosorbent assay in serum samples collected in Months 0 and 7. Pain at the injection site was the most frequently reported local symptom. Two subjects reported medically significant adverse events. Both cases were assessed as unrelated to vaccination by the investigator. In Month 7, 100% seroconversion was observed for both anti-HPV-16 and anti-HPV-18 with high geometric mean antibody titers. HPV-16/18 AS04-adjuvanted vaccine, evaluated for the first time in Chinese females, was generally well tolerated and immunogenic, as previously shown in global studies.
